Tourmaline Bio
Emil deGoma serves as Senior Vice President of Medical Research at Tourmaline Bio since October 2023, following a role as Senior Consultant in Clinical Development at Radiem Consulting, LLC. Previous experience includes leadership positions at several biotechnology and pharmaceutical companies, such as Vice President of Clinical Development at Amgen and ChemoCentryx, and Vice President of Clinical Development at Exicure. Significant therapeutic areas of expertise encompass immunology, nephrology, and cardiovascular disease, with a robust history of managing clinical development activities, presenting to executive leadership, and authoring publications for international conferences. Emil's academic credentials include a Doctor of Medicine from Harvard Medical School and a Bachelor of Arts in Biochemical Sciences from Harvard University, alongside a tenure as an Assistant Professor at the Perelman School of Medicine at the University of Pennsylvania.
This person is not in any offices
Tourmaline Bio
2 followers
Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.